Pentoxifylline-d5
Based on 1 Customer Validation
Pentoxifylline-d5 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.89%
- CAS No.: 1185995-18-9
- Formule: C13H13D5N4O3
- Masse moléculaire:283.34
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1185995-18-9
-
Unlabeled Cas 6493-05-6
-
Appearance Solid
-
Masse moléculaire 283.34
-
Formule C13H13D5N4O3
-
Color White to off-white
-
SMILES
O=C1C2=C(N=CN2C)N(C(N1CCCC([2H])([2H])C(C([2H])([2H])[2H])=O)=O)C
-
Synonyms
BL-191-d5; PTX-d5; Oxpentifylline-d5
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : ≥ 100 mg/mL (352.93 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Iffat Hassan, et al. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014 Oct-Dec; 5(4): 510–516. [Content Brief]
[3]. A Ward, et al. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34(1):50-97. [Content Brief]
[4]. Yessica Cristina Castellanos-Esparza, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52(4):1246-1254. [Content Brief]
[5]. Shabnam Movassaghi, et al. Effect of Pentoxifylline on Ischemia- induced Brain Damage and Spatial Memory Impairment in Rat. Iran J Basic Med Sci. 2012 Sep-Oct; 15(5): 1083-1090. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5293 mL | 17.6466 mL | 35.2933 mL | 88.2332 mL |
| 5 mM | 0.7059 mL | 3.5293 mL | 7.0587 mL | 17.6466 mL | |
| 10 mM | 0.3529 mL | 1.7647 mL | 3.5293 mL | 8.8233 mL | |
| 15 mM | 0.2353 mL | 1.1764 mL | 2.3529 mL | 5.8822 mL | |
| 20 mM | 0.1765 mL | 0.8823 mL | 1.7647 mL | 4.4117 mL | |
| 25 mM | 0.1412 mL | 0.7059 mL | 1.4117 mL | 3.5293 mL | |
| 30 mM | 0.1176 mL | 0.5882 mL | 1.1764 mL | 2.9411 mL | |
| 40 mM | 0.0882 mL | 0.4412 mL | 0.8823 mL | 2.2058 mL | |
| 50 mM | 0.0706 mL | 0.3529 mL | 0.7059 mL | 1.7647 mL | |
| 60 mM | 0.0588 mL | 0.2941 mL | 0.5882 mL | 1.4706 mL | |
| 80 mM | 0.0441 mL | 0.2206 mL | 0.4412 mL | 1.1029 mL | |
| 100 mM | 0.0353 mL | 0.1765 mL | 0.3529 mL | 0.8823 mL |
Pentoxifylline-d5 Related Classifications
HY-B0715S2 Related Classifications
Powered by Bioz